Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Trial of PG4 Multivalent Pneumococcal Vaccine vs Prevnar 20 in Healthy Japanese Infants
jRCT2031260231Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Jun 2026
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of Prevnar 20 in pneumococcal disease (2 arms), sponsored by Pfizer. Primary endpoints: Percentage of participants reporting local reactions within 7 days after each dose, Percentage of participants reporting systemic events within 7 days after each dose and 5 more. Started Jun 2026; status: recruiting.
02
Drugs
Prevnar 20
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on jRCT2031260231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260231.